[{"orgOrder":0,"company":"AltrixBio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"AJN 003","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AltrixBio","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Pill","sponsorNew":"AltrixBio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AltrixBio \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by AltrixBio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FNCE
                          Not Confirmed
                          FNCE
                          Not Confirmed

                          Details : The funding will accelerate the clinical entry of AJN 003, a first-in-class oral therapy designed to transform the treatment of type 2 diabetes and metabolic diseases.

                          Product Name : AJN 003

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 16, 2025

                          Lead Product(s) : AJN 003

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : $5.0 million

                          Deal Type : Series A Financing

                          blank